The US market for Hemostats and Sealants accelerated substantially in Q318 vs Q218
As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market, with the exception of Pfizer, saw revenue growth in Q318. Leading the way were Baxter, with its integration of the Mallinckrodt portfolio, as well as Ethicon and Integra, while Pfizer posted...
Among the many topics covered in the Q318 US Hemostats and Sealants Market Recap are:
The Hemostats and Sealants Market continues to grow at a steady clip. SmartTRAK projects this market will reach more than $3.5B by 2022E with a five-year CAGR of ~5%.
It’s good news for many, but do you know the real story behind those numbers?
SmartTRAK identifies what’s driving growth in the global Hemostats and Sealants market. In this Market Outlook article, Doug Devens, SmartTRAK's Senior Analyst, Biosurgery, does a deep dive, discussing what’s fueling this growth and reviews the top market trends you need to know for the year ahead.
DownloadMarket Outlook: Top Trends to Watch in Hemostats and Sealants
SmartTRAK is excited to be attending ACS - the 2018 Clinical Congress of the American College of Surgeons - on October 21-25 in Boston, Mass.
Doug Devens, Senior Analyst, Biosurgery and Geoffrey Brown, Director Corporate Accounts, Wound Care will be representing SmartTRAK at the conference. Please contact us if you would like schedule a meeting at ASC to see what SmartTRAK can do for you.
The US Surgical Matrices Market advanced again in Q218
In Q218, the US Surgical Matrices Market grew +9.5% YoY according to BioMedGPS’ SmartTRAK Financial Dashboard. The allograft breast matrices and biosynthetic hernia matrices segments outpaced overall market growth, as both posted strong growth in Q218...
Among the many topics covered in the Q218 US Surgical Matrices Recap are:
Baxter, Ethicon and Integra lead the way...
As reported in SmartTRAK’s Financial Dashboard, the US market for Hemostats and Sealants grew +3.8% YoY in Q218, an increase from +3.1% growth rate overall in Q118. Fibrin sealants continue to lead the way with +7.2% YoY growth in Q218, and thrombin hemostats had a very good quarter with +7.2% growth YoY...Among the many topics covered in the full Q218 Hemostats and Sealants Market Recap are:
SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 Hemostats and Sealants Market Recap.
SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 US Surgical Matrices Market Recap.
The US Surgical Matrices Market advanced again in Q417, reaching sales of $338.2MM, up +6.8% YoY, fueled by double-digit growth in allograft breast matrices and biosynthetics hernia matrices.
SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 US Surgical Matrices Market Recap and Financial Dashboard.
Among the many topics covered in the Q417/FY17 US Surgical Matrices Market Recap are:
The US market for Hemostats and Sealants recovered in Q417, up +5.0% YoY, in line with historic growth rates. While biologic sealants continue to lag, every other segment grew, led by absorbable hemostats and fibrin sealants.
SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its 2017 Hemostats & Sealants Market Recap and Financial Dashboard.
As reported in SmartTRAK’s Financial Dashboard, almost every manufacturer competing in the Hemostats and Sealants market saw revenue growth in Q417/FY17, led by Baxter, Ethicon and Cryolife in Q417 and by Baxter and Integra for FY17 ...
Q317 US Surgical Matrices Market: Strong Growth Continues in Breast Matrices
The US Surgical Matrices Market saw growth in Q317 as sales of allografts fueled double-digit growth in breast matrices and biosynthetics offset declines in biologics in hernia repair.
By Doug Devens, Senior Analyst Biosurgery
The US Surgical Matrices market, consisting of hernia repair and breast reconstruction products, continued uneven growth in Q317. Allergan continued to capture share in the overall market, using its growth in allografts to increase its share.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.